Stocks were higher Tuesday afternoon as investors digested earnings reports from several retailers and awaited results from ...

The Dow Jones is treading choppy waters near 44,700 on Tuesday, finding an intraday floor near 44,400 before settling back into the day’s opening bids. The major equity index briefly set another ...

Investors are assessing the likelihood Trump will deliver on his threat to impose fresh tariffs on China, Canada and Mexico.

The pharmaceutical manufacturer Amgen announced on Tuesday that an experimental obesity drug helped patients lose an average of up to 20 percent of their weight in a year.

The thyroid medication levothyroxine may be associated with bone loss, according to a study that will be presented at the ...

Amgen's phase 2 data disappointed, but its obesity pipeline still holds potential. See why AMGN stock is appealing even ...

The company reported a Phase 2 study of its injectable MariTide medicine showed an approximately 20% average weight loss over ...

MariTide was administered monthly or less frequently, which could provide an edge over the popular weekly injections ...

MariTide’s Phase 2 press release “underwhelms” with 20% weight loss from Cohort A and 17% weight loss from Cohort B at 52-weeks, with it being unclear if these are placebo adjusted. MariTide’s weight ...

Amgen (AMGN) reported today the highly anticipated results of a mid-stage trial of its experimental weight loss drug and ...

Amgen stock crashed Tuesday after its weight-loss drug met Wall Street's expectations, but was only on par with Eli Lilly's ...

Amgen's experimental drug MariTide helped overweight or obese patients shed up to 20% of their body weight in a mid-stage ...